Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Benzo[D]Thiazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 1/20 | 0.36 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.35 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.35 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.35 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.35 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.35 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.35 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.35 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.35 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.35 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.95 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.95 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzo[D]Thiazole SCHEMBL27346151 | 1.00 | ALDH1A1 (0.95) | ALDH1A1HSD17B10NPC1RAB9AKDM4E | |
| Benzo[D]Thiazole SCHEMBL29466701 | 0.98 | ALDH1A1 (0.91) | ALDH1A1HSD17B10NPC1RAB9AKDM4E | |
| Benzo[D]Thiazole SCHEMBL28191275 | 0.98 | ALDH1A1 (0.91) | ALDH1A1HSD17B10NPC1RAB9AKDM4E | |
| Benzo[D]Thiazole SCHEMBL10847268 | 0.97 | — | — | |
| Benzo[D]Thiazole SCHEMBL31388426 | 0.97 | — | — | |
| Benzo[D]Thiazole SCHEMBL451685 | 0.97 | — | — | |
| Benzo[D]Thiazole SCHEMBL8430 | 0.97 | — | — | |
| Benzo[D]Thiazole SCHEMBL900814 | 0.97 | ALDH1A1 (1.00) | ALDH1A1HSD17B10NPC1RAB9AKDM4E | |
| Benzo[D]Thiazole SCHEMBL8501381 | 0.95 | ALDH1A1 (0.86) | ALDH1A1HSD17B10NPC1RAB9AKDM4E | |
| Benzo[D]Thiazole SCHEMBL2461444 | 0.95 | ALDH1A1 (0.95) | ALDH1A1HSD17B10NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101909628-B | As leukotriene A4Aryl substituted bridged or fused diamines as hydrolase modulators | JANSSEN PHARMACEUTICA NV | 2013-05-29 | — | — | CN | claimed |
| CN-100591679-C | Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators | JANSSEN PHARMACEUTICA NV | 2010-02-24 | — | — | CN | claimed |
| CN-1860117-A | Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators | JANSSEN PHARMACEUTICA NV (BE) | 2006-11-08 | — | — | CN | claimed |
| JP-2157742-A | — | — | None | — | — | JP | disclosed |
| US-12139499-B2 | Heteroaryl compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| CN-111933802-B | Application of ionic liquid in preparation of perovskite photosensitive layer and perovskite solar cell | 昆山协鑫光电材料有限公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-4284367-A1 | FACTOR XIA INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-115315259-A | Compounds useful for inhibition of ketohexokinase and methods of making and using the same | 因奥必治疗有限公司 | 2022-11-08 | — | — | CN | disclosed |
| WO-2022164735-A1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20210284660-A1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2021-09-16 | — | — | US | disclosed |
| CN-113226356-A | Activating pyruvate kinase R | 福马治疗股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-1216039-A | Process for preparing taxol | UPJOHN CO (US) | 1999-05-05 | — | — | CN | disclosed |
| EP-0772607-A1 | WATER-SOLUBLE METHINE COMPOUND AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER COMPRISING THE SAME | FUJI PHOTO FILM CO., LTD. (JP) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996003393-A1 | WATER-SOLUBLE METHINE COMPOUND AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER COMPRISING THE SAME | FUJI PHOTO FILM CO., LTD. (JP) | 1996-02-08 | — | — | WO | disclosed |
| US-5314747-A | Recording sheets containing cationic sulfur compounds | XEROX CORPORATION (US) | 1994-05-24 | — | — | US | disclosed |
| US-5013638-A | Photographic silver halide element containing small amounts of bromide ions | EASTMAN KODAK COMPANY (US) | 1991-05-07 | — | — | US | disclosed |
| JP-H02157742-A | PHOTOGRAPHIC SILVER HALIDE MATERIAL | EASTMAN KODAK CO | 1990-06-18 | — | — | JP | disclosed |
| EP-0365220-A2 | Photographic silver halide material | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1990-04-25 | — | — | EP | disclosed |
| US-4128586-A | Catalytic reduction of aromatic sulfonyl halides with hydrogen sulfide to yield aromatic thiols | ALLIED CHEMICAL CORPORATION (US) | 1978-12-05 | — | — | US | disclosed |
| US-4064261-A | TRIAZOLOBENOXAZOLE, TRIAZOLOBENZOTHIAZOLE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1977-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12139499-B2 | Heteroaryl compounds for treating Huntington's disease | HTT, HYPK, HDAC6 | MAPK14 4079/4885SLC6A3 343/4885ADRA2A 3851/4885 |
| US-20210284660-A1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, HDAC6 | MAPK14 4079/4885SLC6A3 343/4885ADRA2A 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.